Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOLAIR vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular c AMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Treatment of chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/m L. Maintenance: 400-600 mg/day in divided doses.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Adults: 3-8 hours (mean 5.5); children: 1.5-5 hours; increased in hepatic cirrhosis, heart failure, and COPD; decreased in smokers
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by N-demethylation and oxidation. Approximately 10% excreted unchanged in urine.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal (10% unchanged); hepatic metabolism (90%) with metabolites excreted in urine
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
40% bound, primarily to albumin
Approximately 70% bound to plasma proteins, primarily albumin.
0.45 L/kg; approximates total body water; higher in infants
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral: 96% (immediate release); sustained release: 80-100%
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
GFR < 30 m L/min: reduce dose by 50% and monitor serum levels. GFR 30-50 m L/min: reduce dose by 25%.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh Class B: reduce dose by 50%. Class C: reduce dose by 75% or use alternative.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Children 1-9 years: starting dose 10-16 mg/kg/day orally in divided doses every 4-6 hours; max 600 mg/day. Children 9-16 years: 10-16 mg/kg/day; max 800 mg/day. Adjust based on serum levels (5-15 mcg/m L).
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Start at lower end of dosing range (300 mg/day), titrate slowly with close monitoring of serum levels due to decreased clearance.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No FDA black box warning.
None.
Narrow therapeutic index; monitor serum theophylline levels to avoid toxicity.,Risk of serious cardiovascular events (e.g., arrhythmias, seizures) at high serum concentrations.,May exacerbate peptic ulcer disease.,Use caution in patients with hypoxemia, hypertension, or heart failure.,Drug interactions: cimetidine, fluoroquinolones, macrolides, and other CYP450 inhibitors increase levels; phenytoin, rifampin, and smoking decrease levels.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or any component of the formulation,Active peptic ulcer disease,Uncontrolled seizure disorders
Hypersensitivity to theophylline or any component of the formulation.
Dietary changes that affect CYP1A2 activity alter theophylline clearance. High-protein, low-carbohydrate diets increase clearance; high-carbohydrate, low-protein diets decrease clearance. Charcoal-broiled meats and cruciferous vegetables (e.g., broccoli, cabbage) induce metabolism, reducing efficacy. Caffeine-containing foods and beverages can potentiate toxicity and should be limited. Consistent dietary habits are critical to maintain stable serum levels.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Theophylline (active ingredient in THEOLAIR) is classified as FDA Pregnancy Category C. Human data do not indicate a major teratogenic risk; however, a small increased risk of congenital anomalies cannot be excluded. First trimester: No consistent evidence of teratogenicity; some studies suggest possible association with cardiac defects. Second/third trimester: May cause fetal tachycardia, irritability, and jitteriness due to transplacental passage; neonatal withdrawal symptoms possible. Avoid use near term if possible.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.72. Concentrations in milk are about 60% of maternal serum. Breastfeeding is generally considered safe if maternal levels are therapeutic; however, irritability and insomnia in infants have been reported. Monitor infant for signs of caffeine-like effects. Use with caution, especially in preterm infants.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Pregnancy may decrease theophylline clearance by about 30% due to reduced protein binding and increased volume of distribution, but changes can vary. Dose adjustments should be guided by serum level monitoring. Typical starting dose: 400 mg/day oral, titrated to levels 5–15 mcg/m L. Increased doses may be needed in later pregnancy due to altered pharmacokinetics. Postpartum, clearance may increase, requiring dose reduction.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Theophylline (THEOLAIR) has a narrow therapeutic index (5-15 mg/L). Monitor serum levels due to inter- and intra-patient variability. Coadministration with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) or inducers (e.g., phenytoin, smoking) requires dose adjustments. Use with caution in patients with hepatic impairment, congestive heart failure, or fever, as clearance is reduced.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not double the dose if missed.,Avoid changes in smoking habits, diet, or new medications without consulting your doctor.,Report nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Do not consume large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects.,Maintain consistent intake of high-protein or low-protein diets.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOLAIR vs AEROLATE JR, answered by our medical review team.
THEOLAIR is a Bronchodilator that works by Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular c AMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOLAIR and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOLAIR is: Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/m L. Maintenance: 400-600 mg/day in divided doses.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOLAIR and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOLAIR is classified as Category C. Theophylline (active ingredient in THEOLAIR) is classified as FDA Pregnancy Category C. Human data do not indicate a major teratogenic risk; however, a small increased risk of cong. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.